Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

A clinical trial update wiped out billions in the French company's market cap and raised questions over a potential takeover.

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced ...

Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

Investors in Krystal Biotech, Inc. KRYS need to pay close attention to the stock based on moves in the options market lately. That is because the June 18, 2026 $200.00 Call had some of the highest ...

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

This Biotech Stock Is Up 85%. FDA Has Agreed to Review a Skin Cancer Drug. Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

The structural advantages that allow China to conduct clinical trials more quickly and at lower costs should be leveraged to ...

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but ...